Published in Psychopharmacology (Berl) on October 19, 2005
The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia. J Palliat Med (2013) 2.00
Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr Neuropharmacol (2008) 1.55
Intrathecal treatment with sigma1 receptor antagonists reduces formalin-induced phosphorylation of NMDA receptor subunit 1 and the second phase of formalin test in mice. Br J Pharmacol (2006) 1.16
Activation of the spinal sigma-1 receptor enhances NMDA-induced pain via PKC- and PKA-dependent phosphorylation of the NR1 subunit in mice. Br J Pharmacol (2008) 1.08
Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization. Br J Pharmacol (2012) 1.07
Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptors. Psychopharmacology (Berl) (2009) 0.94
Genetic inactivation and pharmacological blockade of sigma-1 receptors prevent paclitaxel-induced sensory-nerve mitochondrial abnormalities and neuropathic pain in mice. Mol Pain (2014) 0.82
Sigma-1 receptor inhibition reverses acute inflammatory hyperalgesia in mice: role of peripheral sigma-1 receptors. Psychopharmacology (Berl) (2014) 0.78
The selective sigma-1 receptor antagonist E-52862 attenuates neuropathic pain of different aetiology in rats. Sci Rep (2016) 0.76
Sigma-1 receptors control immune-driven peripheral opioid analgesia during inflammation in mice. Proc Natl Acad Sci U S A (2017) 0.75
Ethical guidelines for investigations of experimental pain in conscious animals. Pain (1983) 17.70
Animal models of nociception. Pharmacol Rev (2001) 5.76
Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci U S A (1996) 3.39
Modified formalin test: characteristic biphasic pain response. Pain (1989) 3.00
Genetic enhancement of inflammatory pain by forebrain NR2B overexpression. Nat Neurosci (2001) 2.72
A proposal for the classification of sigma binding sites. Trends Pharmacol Sci (1992) 2.65
International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev (1996) 2.43
Sigma receptors: biology and function. Pharmacol Rev (1990) 2.37
The contribution of excitatory amino acids to central sensitization and persistent nociception after formalin-induced tissue injury. J Neurosci (1992) 1.93
Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Ther (2005) 1.69
Sigma receptors: biology and therapeutic potential. Psychopharmacology (Berl) (2004) 1.66
Cloning and structural analysis of the cDNA and the gene encoding the murine type 1 sigma receptor. Biochem Biophys Res Commun (1997) 1.66
Immunocytochemical localization of the sigma(1) receptor in the adult rat central nervous system. Neuroscience (2000) 1.64
Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. Eur J Pharmacol (1992) 1.57
Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat. J Pharmacol Exp Ther (1997) 1.50
The interaction between neuroactive steroids and the sigma1 receptor function: behavioral consequences and therapeutic opportunities. Brain Res Brain Res Rev (2001) 1.37
Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther (1994) 1.34
Hypoalgesia in mice with a targeted deletion of the tachykinin 1 gene. Proc Natl Acad Sci U S A (1998) 1.31
Formalin-induced pain is reduced in sigma(1) receptor knockout mice. Eur J Pharmacol (2005) 1.21
The involvement of dopamine in nociception: the role of D(1) and D(2) receptors in the dorsolateral striatum. Brain Res (2000) 1.14
Sigma1 receptor modulation of opioid analgesia in the mouse. J Pharmacol Exp Ther (2002) 1.09
Cloning and characterization of a mouse sigma1 receptor. J Neurochem (1998) 1.08
Selective antagonism of opioid analgesia by a sigma system. J Pharmacol Exp Ther (1994) 1.03
A tail withdrawal procedure for assessing analgesic activity in rhesus monkeys. J Pharmacol Methods (1986) 1.03
Acute antinociceptive responses in single and combinatorial opioid receptor knockout mice: distinct mu, delta and kappa tones. Eur J Neurosci (2003) 0.98
Sigma ligands indirectly modulate the NMDA receptor-ion channel complex on intact neuronal cells via sigma 1 site. J Neurosci (1995) 0.98
Antagonism of N-methyl-D-aspartate receptors by sigma site ligands: potency, subtype-selectivity and mechanisms of inhibition. J Pharmacol Exp Ther (1997) 0.97
Analgesia produced by normal doses of opioid antagonists alone and in combination with morphine. Pain (1989) 0.97
In vivo electrophysiological evidence for a selective modulation of N-methyl-D-aspartate-induced neuronal activation in rat CA3 dorsal hippocampus by sigma ligands. J Pharmacol Exp Ther (1992) 0.97
Sigma antagonists potentiate opioid analgesia in rats. Neurosci Lett (1995) 0.96
Antinociceptive effects of choline against acute and inflammatory pain. Neuroscience (2005) 0.95
The effects of sigma ligands and of neuropeptide Y on N-methyl-D-aspartate-induced neuronal activation of CA3 dorsal hippocampus neurones are differentially affected by pertussin toxin. Br J Pharmacol (1994) 0.95
Protein kinase C-dependent potentiation of intracellular calcium influx by sigma1 receptor agonists in rat hippocampal neurons. J Pharmacol Exp Ther (2003) 0.95
Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol. Mol Pharmacol (1996) 0.94
Spinal gabapentin is antinociceptive in the rat formalin test. Neurosci Lett (1997) 0.93
Expression of the purported sigma(1) (sigma(1)) receptor in the mammalian brain and its possible relevance in deficits induced by antagonism of the NMDA receptor complex as revealed using an antisense strategy. J Chem Neuroanat (2000) 0.93
Antinociceptive profile of the pseudopeptide B2 bradykinin receptor antagonist NPC 18688 in mice. Br J Pharmacol (1996) 0.91
Opioid antagonists and antisera to endogenous opioids increase the nociceptive response to formalin: demonstration of an opioid kappa and delta inhibitory tone. J Pharmacol Exp Ther (1996) 0.90
Correlation between neuroleptic binding to sigma(1) and sigma(2) receptors and acute dystonic reactions. Eur J Pharmacol (2000) 0.90
Involvement of sigma receptors in the modulation of the glutamatergic/NMDA neurotransmission in the dopaminergic systems. Eur J Pharmacol (1999) 0.88
Effects of serine/threonine protein phosphatase inhibitors on morphine-induced antinociception in the tail flick test in mice. Eur J Pharmacol (2003) 0.88
Modulation by sigma ligands of N-methyl-D-aspartate-induced [3H]noradrenaline release in the rat hippocampus: G-protein dependency. Naunyn Schmiedebergs Arch Pharmacol (1992) 0.88
Dopamine receptor subtypes and formalin test analgesia. Pharmacol Biochem Behav (1991) 0.87
Is the second phase of the formalin test useful to predict activity in chronic constriction injury models? A pharmacological comparison in different species. Pain Pract (2003) 0.86
Enhanced kappa-opioid receptor-mediated analgesia by antisense targeting the sigma1 receptor. Eur J Pharmacol (1997) 0.84
Chemically-diverse ligands at the glycine B site coupled to N-methyl-D-aspartate (NMDA) receptors selectively block the late phase of formalin-induced pain in mice. Neurosci Lett (1994) 0.83
Naloxone causes apparent antinociception and pronociception simultaneously in the rat paw formalin test. Eur J Pharmacol (1993) 0.83
Metabolites of haloperidol display preferential activity at sigma receptors compared to dopamine D-2 receptors. Eur J Pharmacol (1990) 0.83
The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization. Pain (1997) 0.83
Effects of low and high doses of selective sigma ligands: further evidence suggesting the existence of different subtypes of sigma receptors. Psychopharmacology (Berl) (1997) 0.82
Systemic administration of naloxone produces analgesia in BALB/c mice in the formalin pain test. Neurosci Lett (1988) 0.82
Evaluation of the effects of the enantiomers of reduced haloperidol, azaperol, and related 4-amino-1-arylbutanols on dopamine and sigma receptors. J Med Chem (1993) 0.81
Roles of endogenous opioid peptides in modulation of nocifensive response to formalin. J Pharmacol Exp Ther (2002) 0.80
Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Life Sci (1996) 0.80
Modulation of the neuronal response to N-methyl-D-aspartate by selective sigma2 ligands. Synapse (1998) 0.79
Spinal pain suppression mechanisms may differ for phasic and tonic pain. Brain Res (1985) 0.79
Characterization of haloperidol and trifluperidol as subtype-selective N-methyl-D-aspartate (NMDA) receptor antagonists using [3H]TCP and [3H]ifenprodil binding in rat brain membranes. J Pharmacol Exp Ther (1997) 0.78
Systemic naloxone does not affect pain-related behaviour in the formalin test in rat. Physiol Behav (1988) 0.78
Changes in nociception after lesions of descending serotonergic pathways induced with 5,6-dihydroxytryptamine. Different effects in the formalin and tail-flick tests. Neuropharmacology (1985) 0.78
Actions of butyrophenones and other antipsychotic agents at NMDA receptors: relationship with clinical effects and structural considerations. Neurochem Int (1999) 0.77
Behavior modification and haloperidol in chronic facial pain. South Med J (1979) 0.76
Naloxone reversal of morphine analgesia but failure to alter reactivity to pain in the formalin test. Life Sci (1978) 0.75
Sigma-1 receptors regulate activity-induced spinal sensitization and neuropathic pain after peripheral nerve injury. Pain (2009) 1.75
Formalin-induced pain is reduced in sigma(1) receptor knockout mice. Eur J Pharmacol (2005) 1.21
Phenytoin differentially modulates the affinity of agonist and antagonist ligands for sigma 1 receptors of guinea pig brain. Synapse (2005) 0.98
Irreversible blockade of sigma-1 receptors by haloperidol and its metabolites in guinea pig brain and SH-SY5Y human neuroblastoma cells. J Neurochem (2007) 0.97
Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptors. Psychopharmacology (Berl) (2009) 0.94
Pharmacological activation of 5-HT7 receptors reduces nerve injury-induced mechanical and thermal hypersensitivity. Pain (2010) 0.89
Effects of serine/threonine protein phosphatase inhibitors on morphine-induced antinociception in the tail flick test in mice. Eur J Pharmacol (2003) 0.88
Genetic inactivation and pharmacological blockade of sigma-1 receptors prevent paclitaxel-induced sensory-nerve mitochondrial abnormalities and neuropathic pain in mice. Mol Pain (2014) 0.82
Differences in the allosteric modulation by phenytoin of the binding properties of the sigma1 ligands [3H](+)-pentazocine and [3H]NE-100. Synapse (2006) 0.81
Antiallodynic and analgesic effects of maslinic acid, a pentacyclic triterpenoid from Olea europaea. J Nat Prod (2013) 0.81
σ1 receptors are involved in the visceral pain induced by intracolonic administration of capsaicin in mice. Anesthesiology (2013) 0.80
Role of Na(+), K(+)-ATPase in morphine-induced antinociception. J Pharmacol Exp Ther (2003) 0.80
S1RA, a selective sigma-1 receptor antagonist, inhibits inflammatory pain in the carrageenan and complete Freund's adjuvant models in mice. Behav Pharmacol (2014) 0.80
Predicting the antinociceptive efficacy of σ(1) receptor ligands by a novel receptor fluorescence resonance energy transfer (FRET) based biosensor. J Med Chem (2013) 0.79
Sigma-1 receptor and inflammatory pain. Inflamm Res (2015) 0.77
The antinociceptive effect of morphine is reversed by okadaic acid in morphine-naive but not in morphine-tolerant mice. Pharmacol Biochem Behav (2006) 0.77
Sigma-1 receptors do not regulate calcium influx through voltage-dependent calcium channels in mouse brain synaptosomes. Eur J Pharmacol (2011) 0.75
Changes in morphine-induced activation of cerebral Na(+),K(+)-ATPase during morphine tolerance: biochemical and behavioral consequences. Biochem Pharmacol (2012) 0.75